Morbidity and Mortality after Surgery for Retroperitoneal Sarcoma

Curr Oncol. 2022 Dec 29;30(1):492-505. doi: 10.3390/curroncol30010039.

Abstract

Retroperitoneal sarcoma (RPS) is a rare disease with over 100 histologic types and accounts for 10-15% of all soft tissue sarcomas. Due to the rarity of RPS, sarcoma centers in Europe and North America have created the Transatlantic RPS Working Group (TARPSWG) to study this disease and establish best practices for its management. Current guidelines dictate complete resection of all macro and microscopic disease as the gold standard for patients with RPS. Complete extirpation often requires a multi-visceral resection. In addition, recent evidence suggests that en bloc compartmental resections are associated with reduced rates of local recurrence. However, this approach must be balanced by the potential for added morbidity. Strategies to mitigate postoperative complications include optimization of the patient through improved preoperative nutrition and pre-habilitation therapy, referral to a high-volume sarcoma center, and implementation of enhanced recovery protocols. This review will focus on the factors associated with perioperative complications following surgery for RPS and outline approaches to mitigate poor surgical outcomes in this patient population.

Keywords: morbidity; mortality; retroperitoneal sarcoma; surgery.

Publication types

  • Review

MeSH terms

  • Europe / epidemiology
  • Humans
  • Morbidity
  • Postoperative Complications / epidemiology
  • Retroperitoneal Neoplasms*
  • Sarcoma* / pathology
  • Soft Tissue Neoplasms*

Grants and funding

This research received no external funding.